# Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

> **NCT03599362** · PHASE2 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 7 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Nivolumab + Cabiralizumab
- **RADIATION:** Stereotactic Body Radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT03599362
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-31
- **Primary completion:** 2020-06-15
- **Final completion:** 2020-06-15
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** PI departure from institution
- **Last updated:** 2021-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03599362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03599362, "Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03599362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*